Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on the OMX Nordic Exchange Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abello, Bayer HealthCare, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA. More information is available at http://www.bioinvent.com.

(1) "The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism," September 15, 2008, p.1.

(2) "Changes in Surgical Loads and Economic Burden of Hip and Knee Replacements in the US: 1997-2004," Sunny Kim, Arthritis & Rheumatism (Arthritis Care & Research), April 15, 2008; 59:4, pp. 481-488.

    ThromboGenics NV
    Gaston Geenslaan 1
    B-3001 Leuven
    Belgium
    Tel: +32(0)16-75-13-10
   http://www.thrombogenics.com

    BioInvent International AB (publ)
    Co. reg. No. 556537-7263,
    Address: Solvegatan 41
    Mailing address: SE-223 70 LUND
    Tel: +46(0)46-286-8
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Davis, California (PRWEB) January 22, 2015 ... of Accelerator Mass Spectrometry (AMS) services to the pharmaceutical ... PhD has joined the company in the position of ... 30 years of broad and valuable experience in drug ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2
... world leader in clinical,solutions for radiation therapy and ... technology to implement clinical treatments with,Volumetric Modulated Arc ... in Europe, the way has been cleared for ... Hospital Vienna in Austria to treat cancer using,Elekta,s ...
... KIRKLAND, Wash., Jan. 18 In response to the,recent ... of,class action lawsuits, CellCyte Genetics Corporation (the "Company") (OTC,Bulletin ... merit and,will be shown to be so in a ... international law firm of Duane Morris LLP as its ...
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) ... journal, will publish an article entitled ,Results ... failure (ACCLAIM,trial): a placebo-controlled randomised trial, in ... The article describes the results from,Vasogen,s 2,400-patient ...
Cached Biology Technology:Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability 2Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability 3CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases 2CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases 3The Lancet Publishes Vasogen's ACCLAIM Results 2The Lancet Publishes Vasogen's ACCLAIM Results 3The Lancet Publishes Vasogen's ACCLAIM Results 4The Lancet Publishes Vasogen's ACCLAIM Results 5
(Date:12/22/2014)... DENVER , Dec. 22, 2014  The 2014 Holiday ... industry as Acuity Market Intelligence reports that the long ... Acuity forecasts that intensifying demand for smart phones, tablets, ... a global market of 2.5 billion users with nearly ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
(Date:12/17/2014)... , Dec. 15, 2014 The Defense Logistics Agency ... detect and prevent counterfeit microcircuits from entering into its ... an in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The ... increasing their reliability throughout the supply chain. The new ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... BLOOMINGTON, Ind. -- Studying self-replicating genetic units, called ... pathogenic soil bacteria -- the crown-gall-disease-causing microorganism ... showing how freeloading, mutant derivatives of these plasmids ... heavy-lifting of initiating infection in plant hosts. The ...
... (GIS) Associate Director of Genomic Technologies, Dr Yijun RUAN, ... configuration, revealing how genes interact/communicate and influence each other, ... other. This discovery is crucial in understanding how human ... transcription regulation and coordination takes place in human cells. ...
... Spotted salamanders exposed to contaminated roadside ponds are ... paper in Scientific Reports. This study provides the first ... negative effects of roads apparently by evolving rapidly. ... a host of contaminants from road runoff. Chief among ...
Cached Biology News:Bacterial plasmids -- the freeloading and the heavy-lifters -- balance the high price of disease 2Singapore scientists lead in 3D mapping of human genome to help understand human diseases 2Road runoff spurring spotted salamander evolution 2
Rad 50 Immunogen: c-terminal mRad 50 (604 amino acids). Storage: 4 C...
...
... Kit Includes: Sufficient library for 10 ... 10^9 independent sequences, -28 gIII Sequencing ... sequencing, -96 gIII Sequencing Primer (100 ... E. coli strain ER2738, Control target ...
... The CHEMICON Re-Blot Western Blot ... of antibodies from Western blots that ... radioactive iodine or other isotopes. It ... substrates (TMB, DAB, 4-chloronapthol, etc.), as ...
Biology Products: